Skip to main content

Peer Review reports

From: Heterogeneous constitutional mismatch repair deficiency with MSH6 missense mutation clinically benefits from pembrolizumab and regorafenib combination therapy: a case report and literature review

Original Submission
6 Aug 2020 Submitted Original manuscript
5 Dec 2020 Reviewed Reviewer Report - Magdalena Ratajska
Resubmission - Version 2
Submitted Manuscript version 2
2 Jan 2021 Editorially accepted
9 Jan 2021 Article published 10.1186/s13053-021-00165-2

You can find further information about peer review here.

Back to article page